BridgeBio Pharma (BBIO) Panoramica del titolo
BridgeBio Pharma, Inc. è un'azienda biofarmaceutica che scopre, sviluppa e distribuisce farmaci per pazienti affetti da malattie genetiche. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 1/6 |
| Dividendi | 0/6 |
BBIO Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
BridgeBio Pharma
189.8% sopravvalutato sconto intrinseco
Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins
View narrativeAN
Published 19 Jul
Concorrenti di BridgeBio Pharma, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$72.44 |
| Massimo di 52 settimane | US$93.42 |
| Minimo di 52 settimane | US$48.78 |
| Beta | 0.97 |
| Variazione di 1 mese | -9.29% |
| Variazione a 3 mesi | 8.70% |
| Variazione di 1 anno | 40.74% |
| Variazione a 3 anni | 153.82% |
| Variazione a 5 anni | 47.18% |
| Variazione dall'IPO | 162.94% |
Notizie e aggiornamenti recenti
Recent updates
Seeking Alpha • Sep 10
BridgeBio Pharma: Attruby Peak Sales Set To Rise
Summary BridgeBio Pharma has delivered multiple clinical and commercial successes, yet shares have repeatedly sold off after positive catalysts. Infigratinib's dwarfism trial outperformed the market leader, and Attruby continues to beat sales estimates, with management now guiding higher peak sales. Recent competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction further strengthen BBIO's commercial outlook. I maintain a valuation of at least $100 per share today, with a long-term target of $300+, reflecting robust pipeline execution and rising revenue estimates. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 26
BBIO: ATTR Cardiomyopathy Launch And Three Priority Reviews Will Reprice Shares
Analysts raised the BridgeBio Pharma fair value estimate from $135.94 to $139.85. This reflects updated views on Attruby revenue trends, pipeline progress, and revised P/E assumptions after a series of mixed but generally higher Street price targets through 2026.Articolo di analisi • Aug 13
Analysts Have Made A Financial Statement On BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Second-Quarter Report
Investors in BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) had a good week, as its shares rose 2.3% to close at US$83.84...
Aggiornamento narrativa • Aug 12
BBIO: Multiple Priority Reviews And Rare Disease Launches Will Drive Post 2026 Upside
BridgeBio Pharma's updated analyst price target has nudged higher to about $108, with analysts pointing to continued progress for Attruby, multiple NDAs now under regulatory review, and an active rare disease pipeline as key drivers for the refined outlook. Analyst Commentary Recent Street research on BridgeBio Pharma highlights a mix of confidence in the company’s rare disease portfolio and some caution around competitive and payer related risks.Aggiornamento narrativa • Jul 25
BBIO: Rare Disease Launch Wave And Priority Reviews Will Drive Post 2026 Upside
BridgeBio Pharma's fair value estimate has been revised slightly higher to $105.26 per share from $102.71, as analysts refresh models around updated price targets and pipeline expectations, particularly for Attruby, acoramidis and BBP-418. Analyst Commentary Recent research updates on BridgeBio Pharma reflect a mix of optimism and caution, with analysts recalibrating price targets as Attruby, acoramidis, BBP-418 and infigratinib progress through launch and regulatory milestones.
Nuova narrativa • Jul 19
Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins
The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight. Here is why the market is mispricing the structural hurdles for BBIO: 1.
Aggiornamento narrativa • Jul 11
BBIO: Cardiomyopathy Launch And Rare Disease Filings Will Shape Next Phase
The analyst fair value estimate for BridgeBio Pharma has been raised from $76.00 to $80.00, reflecting updated Street price targets around $96 to $104 and analyst views that recent regulatory progress and ongoing launch execution support slightly higher projected growth, margins, and future P/E. Analyst Commentary Recent research on BridgeBio Pharma shows a mix of optimism around its rare disease portfolio and a more cautious stance from some bearish analysts who are focused on execution and valuation risks.Aggiornamento narrativa • Jun 22
BBIO: ATTR Cardiomyopathy Rollout And Rare Disease NDA Milestones Will Reprice Shares
BridgeBio Pharma's updated analyst price target framework reflects a modestly higher fair value estimate of about $136, as analysts factor in mixed Street revisions that incorporate recent Q1 model updates, new coverage tied to Attruby and the rare disease pipeline, and differing views on payer risks and the recent regulatory milestones. Analyst Commentary Street commentary on BridgeBio Pharma currently reflects a mix of enthusiasm around Attruby, the rare disease portfolio, and key regulatory updates, offset by caution around payer dynamics and how these factors could influence valuation over time.Aggiornamento narrativa • Jun 05
BBIO: Priority Review Rare Disease Pipeline Will Drive Post 2026 Upside
Analysts raised their blended fair value estimate for BridgeBio Pharma by about $1.82 to roughly $102.71, citing fresh price targets around $98 to $104, growing confidence in the Attruby launch, the broader rare disease pipeline, and added visibility from BBP-418's FDA Priority Review. Analyst Commentary Street research on BridgeBio Pharma is mixed, with several firms adjusting price targets and ratings around the Attruby launch, pipeline milestones, and regulatory updates such as the Priority Review for BBP-418.Aggiornamento narrativa • May 20
BBIO: Cardiomyopathy Launch And Late Stage Filings Will Drive Next Phase
BridgeBio Pharma's fair value estimate has been trimmed by $4 to $76 as analysts balance a higher discount rate and more measured revenue growth against ongoing support for Attruby and the broader pipeline, as reflected in recent price target updates across the Street. Analyst Commentary Street research on BridgeBio continues to cluster around Attruby execution, valuation upside tied to pipeline milestones, and the impact of tafamidis settlement dynamics.Aggiornamento narrativa • May 01
BBIO: Attruby Launch And Achondroplasia Data Will Support Post 2026 Upside
Analysts have inched their average price target for BridgeBio higher, with fair value estimates moving from about $100.61 to $100.89 as they factor in updated views on Attruby traction, achondroplasia data, and the potential impact of recent settlement headlines with large pharma peers. Analyst Commentary Street research on BridgeBio has been active, with price targets and fair value estimates moving as analysts update their views on Attruby uptake, achondroplasia data, and the implications of recent settlement headlines with large pharmaceutical peers.Aggiornamento narrativa • Apr 17
BBIO: Attruby Momentum And Late Stage Pipeline Will Support Post 2026 Confidence
Analysts have nudged their fair value target for BridgeBio Pharma higher, from $100.05 to $100.61, citing stronger assumptions around Attruby traction, a wider late stage pipeline, and updated P/E expectations reflected in recent price target hikes across several firms. Analyst Commentary Street research around BridgeBio has been active, with several firms updating models after Q4 Attruby data, infigratinib readouts and fresh coverage initiations.Aggiornamento narrativa • Apr 03
BBIO: ATTR-CM Franchise And Achondroplasia Program Are Expected To Reprice Shares
Analysts slightly raised their average price target on BridgeBio Pharma to $132.57 per share, citing updated models that factor in recent Attruby sales trends, positive infigratinib achondroplasia data, and the company’s progress toward becoming a multi-product commercial business. Analyst Commentary Bullish analysts have been steadily lifting their price targets on BridgeBio Pharma in recent months, reflecting updated views on valuation that incorporate Attruby sales, late stage pipeline progress, and the company’s push toward a broader commercial footprint.Aggiornamento narrativa • Mar 20
BBIO: Late-Stage Genetic Programs And ATTR-CM Franchise Are Expected To Reprice Shares
The updated analyst price target for BridgeBio Pharma moves to $132.57, reflecting analysts' focus on stronger fair value assumptions, a slightly lower discount rate, and higher projected profit margins supported by recent research pointing to Attruby's momentum and late stage pipeline progress. Analyst Commentary Recent Street research points to a cluster of bullish analysts revisiting their models on BridgeBio Pharma, with several lifting fair value estimates and highlighting execution around Attruby and the late stage pipeline.Aggiornamento narrativa • Mar 05
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Beyond 2026
The analyst fair value estimate for BridgeBio Pharma has increased from $89.79 to $100.05, reflecting a series of upward revisions to Street price targets as analysts factor in stronger Attruby sales trends and progress across the broader late-stage pipeline. Analyst Commentary Recent research updates cluster around two main themes for BridgeBio Pharma: valuation support from Attruby, and expectations for the broader late stage pipeline.Aggiornamento narrativa • Feb 19
BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase
The analyst price target for BridgeBio Pharma has been reset from $41 to $80, with analysts citing recent price target increases across the Street and positive Phase 3 PROPEL 3 achondroplasia data as key supports for the higher fair value view. Analyst Commentary Recent Street research has pointed to higher price targets for BridgeBio Pharma following the Phase 3 PROPEL 3 readout and updated views on the company’s late stage pipeline.Aggiornamento narrativa • Feb 05
BBIO: Late-Stage Genetic Programs Are Expected To Support Bullish Repricing
Analysts have lifted their price targets on BridgeBio Pharma, supporting a higher implied fair value of about $128 per share as they factor in updated models, a strengthened view of the company’s late stage pipeline and expectations for its genetic disease portfolio. Analyst Commentary Bullish analysts are leaning into a higher fair value framework for BridgeBio, updating models around the genetic disease portfolio and later stage programs.Aggiornamento narrativa • Jan 22
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Into 2026
Analysts have lifted their fair value estimate for BridgeBio Pharma to about $89.79 from roughly $84.65, citing higher modeled revenue growth and profit margins, along with updated expectations for the late stage pipeline and therapies such as Attruby, encaleret and BBP-418. Analyst Commentary Recent research updates highlight a generally constructive stance on BridgeBio Pharma, with multiple firms revising price targets and pointing to the late stage pipeline and commercial traction of key assets as central to their views.Aggiornamento narrativa • Jan 07
BBIO: Late-Stage Genetic Programs Are Expected To Drive Bullish Repricing
Analysts have trimmed their fair value estimate for BridgeBio Pharma slightly to about $108.70 per share from $109.61. This reflects updated views on higher projected revenue growth, a wider profit margin profile, and a lower assumed future P/E multiple informed by recent positive readouts and pipeline driven price target increases across the Street.Aggiornamento narrativa • Dec 24
BBIO: Late-Stage Pipeline Progress Will Drive Bullish Repricing Ahead
BridgeBio Pharma's analyst price target has been raised meaningfully, with fair value estimates climbing from approximately $88 to $110 as analysts factor in stronger visibility on late stage programs like Attruby, infigratinib, encaleret, and BBP-418. These programs collectively de risk the pipeline and support higher long term profitability.Aggiornamento narrativa • Dec 10
BBIO: Late Stage Pipeline Progress Will Drive Confidence Into 2026 And Beyond
Analysts nudged their average price target for BridgeBio Pharma up by about $1 to roughly $84.65 per share, citing stronger than expected Attruby revenue traction, rising conviction in BBP-418 and encaleret Phase 3 success, and greater visibility on multiple late stage catalysts into 2026. Analyst Commentary Bullish analysts are largely aligned on a constructive outlook for BridgeBio, emphasizing upside to current revenue forecasts, increasing confidence in late stage programs, and a clearer path to market for several key assets.Aggiornamento narrativa • Nov 26
BBIO: Positive Regulatory Momentum Will Drive Confidence Ahead Of 2026 Approvals
BridgeBio Pharma's analyst price target has been raised slightly, increasing from $83.11 to $83.65. Analysts cite positive clinical updates, higher probability of regulatory approvals, and stronger than expected revenue performance as key drivers for the upward revision.Aggiornamento narrativa • Nov 10
BBIO: Positive Late-Stage Data Will Drive Confidence Ahead Of 2026 Regulatory Decisions
BridgeBio Pharma's analyst price target has been raised significantly, from approximately $66 to over $83. Analysts cite stronger-than-expected revenue, promising pipeline data, and increased confidence in future product approvals as key drivers for the upward revision.Aggiornamento narrativa • Oct 27
Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
BridgeBio Pharma's analyst price target has been revised upward, with the average fair value increasing modestly from $66.32 to $66.47. Analysts highlight strong early commercial momentum, underappreciated pipeline opportunities, and rising revenue estimates for key assets.Aggiornamento narrativa • Oct 13
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Analysts have raised their price targets on BridgeBio Pharma by as much as $10 to $82 per share. They cite better-than-expected drug uptake, upcoming clinical milestones, and upgraded sales projections as justification for their increased optimism.Aggiornamento narrativa • Sep 29
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
BridgeBio Pharma’s consensus price target was revised upward, driven by stronger-than-expected commercial uptake of Acoramidis (Attruby), upwardly revised peak sales estimates for key assets, and de-risked late-stage pipeline catalysts, resulting in a new price target of $66.32 from $65.10. Analyst Commentary Bullish analysts cite strong commercial momentum and better-than-expected uptake of Acoramidis (Attruby), particularly in transthyretin amyloid cardiomyopathy (ATTR-CM), as driving upward revisions to price targets.Aggiornamento narrativa • Sep 14
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
BridgeBio Pharma’s consensus price target has been raised to $65.10, driven by increasing analyst confidence in its pipeline progress—particularly for ADH1 and BBP-418, ongoing strong sales momentum for Attruby in ATTR-CM, and multiple upcoming catalysts—reflecting a notably improved valuation outlook. Analyst Commentary Bullish analysts are confident in Phase 3 data readouts for pipeline assets, particularly autosomal dominant hypocalcemia type 1 (ADH1) and limb-girdle muscular dystrophy type 2I/R9 (BBP-418), viewing them as underappreciated and meaningful opportunities likely to expand BridgeBio’s addressable market.Aggiornamento narrativa • Aug 30
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Analysts raised BridgeBio Pharma's price target from $62.43 to $63.10, citing stronger-than-expected uptake of Acoramidis (Attruby), major upcoming Phase 3 catalysts, and increased confidence in pipeline diversification and commercial momentum. Analyst Commentary Bullish analysts highlight stronger-than-expected commercial uptake for Acoramidis (Attruby), surpassing initial projections.Rendimenti per gli azionisti
| BBIO | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -3.2% | -5.2% | -0.9% |
| 1Y | 40.7% | 38.0% | 13.9% |
Ritorno vs Industria: BBIO ha superato il US Biotechs che ha restituito 38 % nell'ultimo anno.
Rendimento vs Mercato: BBIO ha superato il mercato US che ha restituito 13.9 % nell'ultimo anno.
Volatilità dei prezzi
| BBIO volatility | |
|---|---|
| BBIO Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: BBIO non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di BBIO è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2015 | 1,001 | Neil Kumar | bridgebio.com |
BridgeBio Pharma, Inc. è un'azienda biofarmaceutica che scopre, sviluppa e distribuisce farmaci per pazienti affetti da malattie genetiche. L'azienda offre Attruby, una piccola molecola orale di nuova generazione che stabilizza la TTR quasi completa per il trattamento della cardiomiopatia di tipo selvatico o dell'amiloidosi mediata da transtiretina (ATTR-CM); Fosdenopterin, una formulazione endovenosa di piranopterina monofosfato ciclica sintetica per il trattamento della carenza del cofattore molibdeno con il marchio NULIBRY; e infigratinib a basso dosaggio, un inibitore selettivo della tirosin-chinasi FGFR1-3 per via orale, in fase clinica di Fase 3 per il trattamento di bambini affetti da acondroplasia e ipocondroplasia. Sviluppa inoltre Encaleret, una piccola molecola orale, modulatore allosterico negativo del recettore del calcio, che è in fase di studio clinico 3 per il trattamento dell'ipocalcemia autosomica dominante di tipo 1 (ADH1) e dell'ipoparatiroidismo cronico (CHP); BBP-418, una terapia sperimentale a base di piccole molecole somministrate per via orale, in fase di studio clinico di fase 3 per il trattamento della LGMD2I; e BBP-812, una terapia genica sperimentale a base di virus adeno-associato (AAV) per la malattia di Canavan.
BridgeBio Pharma, Inc. Riepilogo dei fondamenti
| BBIO statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$14.16b |
| Utili (TTM) | -US$691.86m |
| Ricavi(TTM) | US$713.07m |
19.9x
Rapporto P/S-20.5x
Rapporto P/EBBIO è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| BBIO Conto economico (TTM) | |
|---|---|
| Ricavi | US$713.07m |
| Costo del fatturato | US$39.66m |
| Profitto lordo | US$673.41m |
| Altre spese | US$1.37b |
| Utili | -US$691.86m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -3.54 |
| Margine lordo | 94.44% |
| Margine di profitto netto | -97.03% |
| Rapporto debito/patrimonio netto | -133.9% |
Come si è comportato BBIO nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/14 17:23 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
BridgeBio Pharma, Inc. è coperta da 36 analisti. 19 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Eliana Merle | Barclays |
| Jason Zemansky | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |